FIELD: immunology.
SUBSTANCE: disclosed are antibodies which specifically bind to human TIGIT, or antigen-binding fragments thereof. Invention also discloses a polynucleotide, an expression vector, a host cell, a method of producing the antibody or a fragment thereof, and a composition. Also, use of the antibody or its fragment, methods of treatment, kits are considered.
EFFECT: present invention can find further application in therapy of various conditions associated with TIGIT.
140 cl, 43 dwg, 18 tbl, 7 ex
| Title | Year | Author | Number |
|---|---|---|---|
| ANTIBODY TO TIGIT AND ITS USE | 2019 |
|
RU2786434C2 |
| ANTI-TIGIT ANTIBODIES AND METHODS OF USE | 2016 |
|
RU2817838C2 |
| STABLE COMPOSITIONS OF ANTI-TIGIT ANTIBODIES, INDIVIDUALLY AND IN COMBINATION WITH ANTIBODIES AGAINST PROGRAMMED DEATH RECEPTOR 1 (PD-1), AND METHODS OF THEIR USE | 2018 |
|
RU2820576C2 |
| MONOCLONAL BINDING AGENTS, THEIR DRUG CONJUGATES AND THEIR APPLICATIONS | 2017 |
|
RU2744914C2 |
| ADAM9-BINDING MOLECULES AND THEIR APPLICATION METHODS | 2017 |
|
RU2783619C2 |
| ANTI-HLA-A2 ANTIBODIES AND THEIR APPLICATION METHODS | 2018 |
|
RU2782276C2 |
| ANTI-DR5 ANTIBODY AND USE THEREOF | 2018 |
|
RU2735956C1 |
| CD131-BINDING PROTEINS AND THEIR APPLICATIONS | 2016 |
|
RU2773927C2 |
| ANTI-PD-L1 AND IL-2 CYTOKINES | 2017 |
|
RU2769282C2 |
| PD-L1 SPECIFIC ANTIBODIES | 2017 |
|
RU2756236C2 |
